Home › Compare › PRVCF vs BTI

PRVCF vs BTI: Dividend Comparison 2026

PRVCF yields 14285.71% · BTI yields 5.38%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PRVCF wins by $1868328188208921344.00M in total portfolio value
10 years
PRVCF
PRVCF
● Live price
14285.71%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1868328188208921344.00M
Annual income
$1,842,950,648,126,759,800,000,000.00
Full PRVCF calculator →
BTI
BTI
● Live price
5.38%
Share price
$58.47
Annual div
$3.15
5Y div CAGR
11.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$37.7K
Annual income
$2,786.64
Full BTI calculator →

Portfolio growth — PRVCF vs BTI

📍 PRVCF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPRVCFBTI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PRVCF + BTI cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
PRVCF pays
BTI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PRVCF
Annual income on $10K today (after 15% tax)
$1,214,285.71/yr
After 10yr DRIP, annual income (after tax)
$1,566,508,050,907,746,000,000,000.00/yr
BTI
Annual income on $10K today (after 15% tax)
$457.40/yr
After 10yr DRIP, annual income (after tax)
$2,368.64/yr
At 15% tax rate, PRVCF beats the other by $1,566,508,050,907,746,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PRVCF + BTI for your $10,000?

PRVCF: 50%BTI: 50%
100% BTI50/50100% PRVCF
Portfolio after 10yr
$934164094104460672.00M
Annual income
$921,475,324,063,379,900,000,000.00/yr
Blended yield
98.64%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BTI right now

PRVCF
No analyst data
Altman Z
-138.3
Piotroski
1/9
BTI
Analyst Ratings
12
Buy
4
Hold
2
Sell
Consensus: Buy
Price Target
$40.00
-31.6% upside vs current
Range: $40.00 — $40.00
Altman Z
2.1
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PRVCF buys
0
BTI buys
0
No recent congressional trades found for PRVCF or BTI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPRVCFBTI
Forward yield14285.71% ✓5.38%
Annual dividend / share$2.00$3.15 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%11.3% ✓
Portfolio after 10y$1868328188208921344.00M ✓$37.7K
Annual income after 10y$1,842,950,648,126,759,800,000,000.00 ✓$2,786.64
Total dividends collected$1866648039868218112.00M ✓$14.3K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: PRVCF vs BTI ($10,000, DRIP)

YearPRVCF PortfolioPRVCF Income/yrBTI PortfolioBTI Income/yrGap
1← crossover$1,439,271$1,428,571.43$11,299$598.92+$1.43M → PRVCF
2$193,699,090$192,159,069.24$12,794$703.91+$193.69M → PRVCF
3$24,376,441,818$24,169,183,791.94$14,518$829.07+$24376.43M → PRVCF
4$2,868,716,750,186$2,842,633,957,441.24$16,513$978.64+$2868716.73M → PRVCF
5$315,716,708,842,374$312,647,181,919,674.60$18,827$1,157.84+$315716708.82M → PRVCF
6$32,495,195,455,130,188$32,157,378,576,668,850.00$21,518$1,373.12+$32495195455.11M → PRVCF
7$3,128,044,259,554,657,300$3,093,274,400,417,667,600.00$24,657$1,632.46+$3128044259554.63M → PRVCF
8$281,631,115,249,329,080,000$278,284,107,891,605,600,000.00$28,329$1,945.74+$281631115249329.06M → PRVCF
9$23,717,327,179,590,366,000,000$23,415,981,886,273,583,000,000.00$32,637$2,325.33+$23717327179590368.00M → PRVCF
10$1,868,328,188,208,921,400,000,000$1,842,950,648,126,759,800,000,000.00$37,708$2,786.64+$1868328188208921344.00M → PRVCF

PRVCF vs BTI: Complete Analysis 2026

PRVCF — Stock

PreveCeutical Medical Inc., a health sciences company, engages in the development of options for preventive and curative therapies utilizing organic and nature identical products. Its pipeline products include Cannabinoid Sol-Gel Delivery, a cannabinoid-based nose-to-brain delivery system that provides relief from various indications, including pain, inflammation, seizures, and neurological disorders; BSV Peptide Program for targeting cancer progression; Non-Addictive Analgesic for pain management; and Dual Gene Therapy for type 2 diabetes and obesity. The company also develops a range of medicinal cannabis-based products. PreveCeutical Medical Inc. is headquartered in Vancouver, Canada.

Full PRVCF Calculator →

BTI — Consumer Staples

British American Tobacco p.l.c. provides tobacco and nicotine products to consumers in the Americas, Europe, the Asia-Pacific, the Middle East, Africa, and the United States. It offers vapour, heated, and modern oral nicotine products; combustible cigarettes; and traditional oral products, such as snus and moist snuff. The company provides its products under the Vuse, glo, Velo, Grizzly, Kodiak, Dunhill, Kent, Lucky Strike, Pall Mall, Rothmans, Newport, Natural American Spirit, and Camel brands. The company distributes its products to retail outlets. British American Tobacco p.l.c. was founded in 1902 and is based in London, the United Kingdom.

Full BTI Calculator →
📬

Get this PRVCF vs BTI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PRVCF vs SCHDPRVCF vs JEPIPRVCF vs OPRVCF vs KOPRVCF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.